Amgen, Inc. vs Etsy Inc — how do they compare? Amgen, Inc. trades at $415.6 (market cap $224.14B), while Etsy Inc trades at $80.04 (market cap $7.29B). The key difference: Amgen, Inc. is far larger — about 30.7× Etsy Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Etsy Inc pays none. Which is the better fit depends on your goals.
| AMGN | ETSY | |
|---|---|---|
Market Cap | $224.14B | $7.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $86.47 |
52-Week Low | $271.18 | $44.05 |
Enterprise Value | $267.45B | $9.25B |
Dividend Yield | 2.43% | — |
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
ETSY trades at $79.42, down 1.22% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $0.98, beating expectations, and raised its full-year outlook while announcing a 12% workforce reduction and a $2 billion share repurchase program. Revenue for 2025 was $2.88 billion with a net income margin of 5.65%, though equity remains negative at -$758.87 million due to retained earnings deficits.
The outlook is mixed: analyst consensus is a Buy with a $85.71 price target, reflecting optimism on operational efficiency and AI-driven growth, but risks include high debt, negative equity, and competitive pressures. The stock's valuation metrics like P/E of 25.15 and P/S of 3.54 suggest moderate pricing relative to peers, with cash flow stability from operations offering support amid restructuring.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →